See more : Kingland Group Holdings Limited (1751.HK) Income Statement Analysis – Financial Results
Complete financial analysis of DICE Therapeutics, Inc. (DICE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DICE Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Zanite Acquisition Corp. (ZNTEU) Income Statement Analysis – Financial Results
- Puma Exploration Inc. (PUMXF) Income Statement Analysis – Financial Results
- FNS Holdings Public Company Limited (FNS.BK) Income Statement Analysis – Financial Results
- Fintech Ecosystem Development Corp. (FEXDU) Income Statement Analysis – Financial Results
- Chijet Motor Company, Inc. (CJET) Income Statement Analysis – Financial Results
DICE Therapeutics, Inc. (DICE)
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 1.13M | 863.00K | 5.78M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 1.13M | 863.00K | 5.78M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 62.56M | 36.51M | 19.58M | 15.72M |
| General & Administrative | 25.66M | 12.22M | 5.00M | 3.61M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.66M | 12.22M | 5.00M | 3.61M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 88.22M | 48.73M | 24.58M | 19.32M |
| Cost & Expenses | 88.22M | 48.73M | 24.58M | 19.32M |
| Interest Income | 5.21M | 136.00K | 139.00K | 635.00K |
| Interest Expense | 679.00K | 174.00K | 13.00K | 26.00K |
| Depreciation & Amortization | 5.21M | 136.00K | 836.00K | 1.34M |
| EBITDA | -83.01M | -47.47M | -22.89M | -12.21M |
| EBITDA Ratio | 0.00% | -4,219.29% | -2,651.80% | -211.36% |
| Operating Income | -88.22M | -47.60M | -23.72M | -13.55M |
| Operating Income Ratio | 0.00% | -4,231.38% | -2,748.67% | -234.58% |
| Total Other Income/Expenses | 4.33M | -1.36M | -18.00K | 609.00K |
| Income Before Tax | -83.89M | -48.96M | -23.74M | -12.94M |
| Income Before Tax Ratio | 0.00% | -4,351.91% | -2,750.75% | -224.03% |
| Income Tax Expense | -2.22M | -487.00K | 13.00K | 26.00K |
| Net Income | -81.66M | -48.47M | -23.75M | -12.96M |
| Net Income Ratio | 0.00% | -4,308.62% | -2,752.26% | -224.48% |
| EPS | -2.07 | -3.91 | -1.02 | -0.56 |
| EPS Diluted | -2.07 | -3.91 | -1.02 | -0.56 |
| Weighted Avg Shares Out | 39.40M | 12.38M | 23.23M | 23.23M |
| Weighted Avg Shares Out (Dil) | 39.40M | 12.38M | 23.23M | 23.23M |
DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
DICE Therapeutics to Present at November Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports